Schizophrenia Breaking News: April 2011
Targacept's drug compound TC-5619 has shown positive effects in improving cognitive functioning and negative symptoms in a Phase 2 trial of people diagnosed with schizophrenia. The company is actively developing plans to move forward with Astra Zeneca in bringing the drug to market. Clinically significant improvements were seen on... Read more


